Journal Article
. 2018 Mar;27(6).
doi: 10.1158/1055-9965.EPI-17-0905.

Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence

Kristen D Brantley 1 Anders Kjærsgaard 2 Deirdre Cronin-Fenton 2 Rami Yacoub 3 Anja S Nielsen 4 Kristina L Lauridsen 4 Stephen Hamilton-Dutoit 4 Timothy L Lash 3 
Affiliations
  • PMID: 29593009
  •     44 References
  •     5 citations

Abstract

Background: Expression of human paracrine hormones stanniocalcin 1 (STC1) and stanniocalcin 2 (STC2) may potentiate late breast cancer recurrence. We tested the hypothesis that expression of STC1 and STC2 in primary breast tumors is more strongly associated with late versus early recurrences.Methods: A total of 541 estrogen receptor-positive, tamoxifen-treated (ER+/TAM+) and 300 ER-negative, tamoxifen-untreated (ER-/TAM-) breast cancer patients who experienced recurrence within 10 years of primary diagnosis and matched recurrence-free controls were selected from a cohort of 11,251 Danish breast cancer patients diagnosed with stage I, II, or III breast cancer during 1985 to 2001. The association between IHC expression of STC1 and STC2 in primary breast tumor tissue microarrays and breast cancer recurrence was evaluated within median time to recurrence quintiles.Results: The association between STC1 expression, dichotomized as positive or negative, and recurrence was strongly positive for the final time quintile (6-10 years postdiagnosis) in the ER+/TAM+ group [aOR = 2.70; 95% confidence interval (CI): 1.22-5.98]. Regression of the log ORs relating dichotomous STC1 and STC2 expression to recurrence by median time to recurrence (year) resulted in a relatively large positive effect estimate for STC1 (β = 0.16; 95% CI, -0.03-0.36) and a near-null positive effect estimate for STC2 (β = 0.04; 95% CI, -0.14-0.21).Conclusions: Our results suggest a stronger association between primary tumor STC1 expression and late recurrence, as opposed to early recurrence, although no clear trend was apparent.Impact: STC1 expression in the primary tumor may potentiate late recurrences, suggesting dormancy pathways that merit further investigation. Cancer Epidemiol Biomarkers Prev; 27(6); 653-9. ©2018 AACR.

Locoregional relapse after breast cancer: most relapses occur late and are not clinically detected.
David A Montgomery, Katherine Krupa, Timothy G Cooke.
Breast J, 2009 Mar 19; 15(2). PMID: 19292802
STC1 expression is associated with tumor growth and metastasis in breast cancer.
Andy C-M Chang, Judy Doherty, +4 authors, Robin L Anderson.
Clin Exp Metastasis, 2014 Nov 14; 32(1). PMID: 25391215
21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.
Benjamin M Parsons, Jeffrey Landercasper, +3 authors, Leah L Dietrich.
Breast Cancer Res Treat, 2016 Aug 11; 159(2). PMID: 27507245    Free PMC article.
Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.
J Stephen, G Murray, +13 authors, J M S Bartlett.
Br J Cancer, 2014 Oct 15; 111(12). PMID: 25314051    Free PMC article.
Breast cancer recurrence in older women five to ten years after diagnosis.
Jaclyn L F Bosco, Timothy L Lash, +6 authors, BOW Investigators.
Cancer Epidemiol Biomarkers Prev, 2009 Oct 22; 18(11). PMID: 19843686    Free PMC article.
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.
Thomas P Ahern, Lars Pedersen, +5 authors, Timothy L Lash.
J Natl Cancer Inst, 2011 Aug 05; 103(19). PMID: 21813413    Free PMC article.
Highly Cited.
Stanniocalcin-1, a new biomarker of glioma progression, is associated with prognosis of patients.
Jingyuan Su, Bingyu Guo, +3 authors, Guobiao Liang.
Tumour Biol, 2015 Mar 19; 36(8). PMID: 25783529
The respiratory effects of stanniocalcin-1 (STC-1) on intact mitochondria and cells: STC-1 uncouples oxidative phosphorylation and its actions are modulated by nucleotide triphosphates.
Joseph P Ellard, Christopher R McCudden, +4 authors, Graham F Wagner.
Mol Cell Endocrinol, 2006 Nov 10; 264(1-2). PMID: 17092635
Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.
K W Andersen, H T Mouridsen.
Acta Oncol, 1988 Jan 01; 27(6A). PMID: 3064772
Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.
Mitch Dowsett, Ivana Sestak, +7 authors, Jack Cuzick.
J Clin Oncol, 2013 Jul 03; 31(22). PMID: 23816962
Highly Cited.
Tumor dormancy: elevated expression of stanniocalcins in late relapsing breast cancer.
Kristiina Joensuu, Päivi Heikkilä, Leif C Andersson.
Cancer Lett, 2008 Mar 22; 265(1). PMID: 18355956
Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1.
Shinya Ohkouchi, Gregory J Block, +6 authors, Darwin J Prockop.
Mol Ther, 2011 Dec 08; 20(2). PMID: 22146344    Free PMC article.
Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
K S McCarty, L S Miller, +2 authors, K S McCarty.
Arch Pathol Lab Med, 1985 Aug 01; 109(8). PMID: 3893381
Highly Cited.
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Martin Filipits, Margaretha Rudas, +25 authors, EP Investigators.
Clin Cancer Res, 2011 Aug 03; 17(18). PMID: 21807638
Highly Cited.
Mammalian stanniocalcins and cancer.
A C-M Chang, D A Jellinek, R R Reddel.
Endocr Relat Cancer, 2003 Sep 25; 10(3). PMID: 14503913
Review.
Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins.
Selma Esseghir, Alan Kennedy, +4 authors, Clare M Isacke.
Clin Cancer Res, 2007 Jun 05; 13(11). PMID: 17545519
Prognostic and Predictive Biomarkers of Endocrine Responsiveness for Estrogen Receptor Positive Breast Cancer.
Cynthia X Ma, Ron Bose, Matthew J Ellis.
Adv Exp Med Biol, 2016 Mar 19; 882. PMID: 26987533
Review.
STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.
Jingjing Wu, Maode Lai, +2 authors, Jian-Jun Wei.
Oncol Rep, 2015 Jul 15; 34(3). PMID: 26165228    Free PMC article.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
M E Charlson, P Pompei, K L Ales, C R MacKenzie.
J Chronic Dis, 1987 Jan 01; 40(5). PMID: 3558716
Highly Cited.
Hypoxic preconditioning induces elevated expression of stanniocalcin-1 in the heart.
Johan A Westberg, Martina Serlachius, Petri Lankila, Leif C Andersson.
Am J Physiol Heart Circ Physiol, 2007 Jun 19; 293(3). PMID: 17573464
Residual risk of breast cancer recurrence 5 years after adjuvant therapy.
Abenaa M Brewster, Gabriel N Hortobagyi, +8 authors, Francisco J Esteva.
J Natl Cancer Inst, 2008 Aug 13; 100(16). PMID: 18695137    Free PMC article.
Highly Cited.
Quality control of end results in a Danish adjuvant breast cancer multi-center study.
P S Hansen, E Andersen, K W Andersen, H T Mouridsen.
Acta Oncol, 1997 Jan 01; 36(7). PMID: 9490088
STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways.
Bing Chen, Xiao Zeng, +7 authors, Shufang Liang.
Oncotarget, 2016 Sep 24; 7(44). PMID: 27662663    Free PMC article.
mRNA expression level of estrogen-inducible gene, alpha 1-antichymotrypsin, is a predictor of early tumor recurrence in patients with invasive breast cancers.
Jun Yamamura, Yasuo Miyoshi, +5 authors, Shinzaburo Noguchi.
Cancer Sci, 2004 Nov 18; 95(11). PMID: 15546506
Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer.
Keisuke Ieta, Fumiaki Tanaka, +8 authors, Masaki Mori.
Int J Cancer, 2009 May 06; 125(4). PMID: 19415750
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
Breast International Group (BIG) 1-98 Collaborative Group, Beat Thürlimann, +13 authors, Aron Goldhirsch.
N Engl J Med, 2005 Dec 31; 353(26). PMID: 16382061
Highly Cited.
Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?
Adam M Brufsky, Nancy E Davidson.
Clin Cancer Res, 2016 Aug 16; 22(20). PMID: 27521446    Free PMC article.
Estrogen Receptor analyses in the Danish Breast Cancer Cooperative Group. History, methods, prognosis and clinical implications.
Maj-Lis M Talman, Birgitte B Rasmussen, Jørn Andersen, Ib J Christensen.
Acta Oncol, 2008 May 10; 47(4). PMID: 18465350
[A case of local recurrence developing thirty-nine years after mastectomy for breast cancer].
Yuko Tashima, Katsunori Kawano.
Gan To Kagaku Ryoho, 2014 Apr 20; 41(3). PMID: 24743283
Review.
Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer.
Yuan-Yu Wang, Li Li, Zhong-Sheng Zhao, Hui-Ju Wang.
World J Surg Oncol, 2013 Apr 04; 11. PMID: 23548070    Free PMC article.
Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany.
Bernd Holleczek, Hermann Brenner.
BMC Cancer, 2012 Jul 31; 12. PMID: 22838641    Free PMC article.
Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer.
Toula Bouras, Melissa C Southey, +6 authors, Deon J Venter.
Cancer Res, 2002 Mar 13; 62(5). PMID: 11888893
Stanniocalcin-1: a novel molecular blood and bone marrow marker for human breast cancer.
Robert A Wascher, Kelly T Huynh, +4 authors, Dave S B Hoon.
Clin Cancer Res, 2003 Apr 10; 9(4). PMID: 12684415
Metastatic breast cancer 39 years after primary treatment.
C C Mamby, R R Love, E Heaney.
Wis Med J, 1993 Oct 01; 92(10). PMID: 8266714
The clinical database and the treatment guidelines of the Danish Breast Cancer Cooperative Group (DBCG); its 30-years experience and future promise.
Susanne Møller, Maj-Britt Jensen, +6 authors, Danish Breast Cancer Cooperative Group.
Acta Oncol, 2008 May 10; 47(4). PMID: 18465317
STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling.
Shuwen Yang, Qinghai Ji, +18 authors, Gong Yang.
Oncotarget, 2016 Nov 20; 8(4). PMID: 27863406    Free PMC article.
Factors predicting late recurrence for estrogen receptor-positive breast cancer.
Ivana Sestak, Mitch Dowsett, +4 authors, Jack Cuzick.
J Natl Cancer Inst, 2013 Sep 14; 105(19). PMID: 24029245    Free PMC article.
Highly Cited.
Stanniocalcin-1 suppresses superoxide generation in macrophages through induction of mitochondrial UCP2.
Yanlin Wang, Luping Huang, +5 authors, David Sheikh-Hamad.
J Leukoc Biol, 2009 Jul 16; 86(4). PMID: 19602668    Free PMC article.
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
Marco Colleoni, Zhuoxin Sun, +8 authors, Aron Goldhirsch.
J Clin Oncol, 2016 Jan 21; 34(9). PMID: 26786933    Free PMC article.
Highly Cited.
Identifying biomarkers to select patients with early breast cancer suitable for extended adjuvant endocrine therapy.
Mark Abramovitz, Amy Krie, +3 authors, Brian Leyland-Jones.
Curr Opin Oncol, 2016 Oct 18; 28(6). PMID: 27606693
Review.
CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
Timothy L Lash, Deirdre Cronin-Fenton, +9 authors, Stephen Hamilton-Dutoit.
J Natl Cancer Inst, 2011 Feb 18; 103(6). PMID: 21325141    Free PMC article.
Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia.
Alice Y S Law, Chris K C Wong.
Exp Cell Res, 2009 Sep 30; 316(3). PMID: 19786016
Minimal residual disease in solid neoplasia: New frontier or red-herring?
Pierre Mordant, Yohann Loriot, +5 authors, Eric Deutsch.
Cancer Treat Rev, 2011 May 27; 38(2). PMID: 21612875
Review.
Stanniocalcin: A molecular guard of neurons during cerebral ischemia.
K z Zhang, P J Lindsberg, +3 authors, L C Andersson.
Proc Natl Acad Sci U S A, 2000 Mar 22; 97(7). PMID: 10725397    Free PMC article.
Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer.
Camilla Coulson-Gilmer, Matthew P Humphries, +14 authors, Valerie Speirs.
J Pathol Clin Res, 2018 Jun 30; 4(4). PMID: 29956502    Free PMC article.
Role of stanniocalcin-1 in breast cancer.
Fengxia Chen, Zhicai Zhang, Feifei Pu.
Oncol Lett, 2019 Oct 04; 18(4). PMID: 31579413    Free PMC article.
Review.
Expression, function and clinical application of stanniocalcin-1 in cancer.
Fangyu Zhao, Gang Yang, +7 authors, Yupei Zhao.
J Cell Mol Med, 2020 May 30; 24(14). PMID: 32468698    Free PMC article.
Review.
Stanniocalcin 1 is a prognostic biomarker in glioma.
Weijian Luo, Dong Chen, Hao Wang, Jiliang Hu.
Oncol Lett, 2020 Aug 13; 20(3). PMID: 32782542    Free PMC article.
Multi-drug resistance protein 2 (MRP2) expression, adjuvant tamoxifen therapy, and risk of breast cancer recurrence: a Danish population-based nested case-control study.
Cathrine F Hjorth, Anja S Nielsen, +4 authors, Deirdre Cronin-Fenton.
Acta Oncol, 2018 Nov 22; 58(2). PMID: 30458661    Free PMC article.